Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143898 | 1.00 | PPARD (0.42) | PPARDMTNR1AMTNR1BPOLBALDH1A1 | |
| SCHEMBL3143895 | 1.00 | PPARD (0.42) | PPARDMTNR1AMTNR1BPOLBALDH1A1 | |
| SCHEMBL3144157 | 0.85 | PDE4D (0.36) | ALDH1A1KMT2ANPC1 | |
| SCHEMBL3144159 | 0.85 | PDE4D (0.36) | ALDH1A1KMT2ANPC1 | |
| SCHEMBL3144902 | 0.79 | L3MBTL1 (0.52) | PPARD | |
| SCHEMBL3145254 | 0.79 | L3MBTL1 (0.52) | PPARD | |
| SCHEMBL2965106 | 0.76 | MTNR1A (0.61) | MTNR1AMTNR1BPOLBALDH1A1KMT2A | |
| SCHEMBL10915417 | 0.75 | ALDH1A1 (0.52) | PPARDPOLBALDH1A1TSHRTDP1 | |
| SCHEMBL11324841 | 0.75 | L3MBTL1 (0.59) | PPARDPOLBALDH1A1TSHRTDP1 | |
| SCHEMBL3807614 | 0.74 | BRD4 (0.58) | POLBALDH1A1LMNAKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | CCR1, CCR4, CCR10 | PPARD 127/4885MTNR1A 126/4885MTNR1B 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.